Open access
Open access
Powered by Google Translator Translator

Gastroenterology (all articles)

Liver cystic echinococcosis: a parasitic review

25 May, 2023 | 11:19h | UTC

Liver cystic echinococcosis: a parasitic review – Therapeutic Advances in Infectious Disease

 

AGA/ACG Guideline | Pharmacological management of chronic idiopathic constipation

22 May, 2023 | 13:53h | UTC

American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation – American Journal of Gastroenterology

 

Review | Hereditary colorectal, gastric, and pancreatic cancer

18 May, 2023 | 13:43h | UTC

Hereditary colorectal, gastric, and pancreatic cancer: comprehensive review – BJS Open

 

Commentary on Twitter

 

Podcast | Dysphagia pearls

18 May, 2023 | 13:42h | UTC

#395 Dysphagia with Dr. Diana Snyder – The Curbsiders

 

RCT | Per-oral endoscopic myotomy outperforms pneumatic dilation for post-laparoscopic heller myotomy achalasia

16 May, 2023 | 14:36h | UTC

The Efficacy of Peroral Endoscopic Myotomy vs Pneumatic Dilation as Treatment for Patients With Achalasia Suffering From Persistent or Recurrent Symptoms After Laparoscopic Heller Myotomy: A Randomized Clinical Trial – Gastroenterology

 

RCT | Prophylactic antibiotics show no statistically significant survival improvement in severe alcohol-related hepatitis

15 May, 2023 | 13:21h | UTC

Summary: This multicenter, randomized, double-blind clinical trial aimed to determine the efficacy of amoxicillin-clavulanate combined with prednisolone compared to placebo combined with prednisolone on mortality in patients hospitalized with severe alcohol-related hepatitis. The study involved 284 patients from 25 centers in France and Belgium with biopsy-proven severe alcohol-related hepatitis, who were followed up for 180 days.

The primary outcome was all-cause mortality at 60 days, while secondary outcomes included mortality at 90 and 180 days, infection rates, hepatorenal syndrome, and changes in Model for End-stage Liver Disease (MELD) and Lille scores. The results showed no statistically significant difference in 60-day mortality between the two groups, with 17.3% in the amoxicillin-clavulanate group and 21.3% in the placebo group. However, infection rates at 60 days were significantly lower in the amoxicillin-clavulanate group compared to the placebo group.

It is worth noting that the study may have been underpowered, as the absolute risk difference of 4% did not achieve statistical significance. In conclusion, the combination of amoxicillin-clavulanate and prednisolone did not show a statistically significant improvement in 2-month survival in patients hospitalized with severe alcohol-related hepatitis compared to prednisolone alone. These findings do not support the use of prophylactic antibiotics to improve survival in this patient population, but the potential underpowered nature of the study should be considered.

Article: Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

 

Commentary on Twitter

 

Review | Heart failure and liver disease: cardiohepatic interactions

15 May, 2023 | 13:06h | UTC

Heart Failure and Liver Disease: Cardiohepatic Interactions – JACC: Heart Failure

 

Review | Nonalcoholic fatty liver disease from a primary care perspective

15 May, 2023 | 12:57h | UTC

Nonalcoholic fatty liver disease from a primary care perspective – Diabetes, Obesity and Metabolism

 

Recent advances in the management of primary sclerosing cholangitis

11 May, 2023 | 11:45h | UTC

Recent Advances in the Management of Primary Sclerosing Cholangitis – Clinical Gastroenterology and Hepatology

Related:

AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma – Hepatology

APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis – Hepatology International

A consensus integrated care pathway for patients with primary biliary cholangitis.

Biliary Endoscopy in the Management of Primary Sclerosing Cholangitis and its Complications

 

Review | Diagnosis and management of cirrhosis and its complications

10 May, 2023 | 16:06h | UTC

Diagnosis and Management of Cirrhosis and Its Complications: A Review – JAMA (free for a limited period)

Author Interview: Management of Cirrhosis in 2023

 

Guideline | Use of non-invasive biomarkers for diagnosis of colorectal neoplasia

10 May, 2023 | 15:46h | UTC

Joint Asian Pacific Association of Gastroenterology (APAGE)–Asian Pacific Society of Digestive Endoscopy (APSDE) clinical practice guidelines on the use of non-invasive biomarkers for diagnosis of colorectal neoplasia – Gut

 

Study shows unenhanced CT shows 30% lower diagnostic accuracy in abdominal pain evaluation

9 May, 2023 | 15:02h | UTC

Diagnostic Accuracy of Unenhanced Computed Tomography for Evaluation of Acute Abdominal Pain in the Emergency Department – JAMA Surgery (free for a limited period)

Editorial: Intravenous Contrast in Computed Tomography Imaging for Acute Abdominal Pain – JAMA Surgery (free for a limited period)

News Release: Bypassing contrast in patients with kidney disease and contrast allergies may lead to less accurate scans – University of Michigan

Commentary: New data suggest clinicians should think twice before foregoing contrast-enhanced imaging – Health Imaging

 

Commentary on Twitter

 

Review | The global burden of liver disease

5 May, 2023 | 15:23h | UTC

The Global Burden of Liver Disease – Clinical Gastroenterology and Hepatology

 

Review | Identifying, understanding and managing fecal urgency in inflammatory bowel diseases

4 May, 2023 | 13:38h | UTC

Identifying, understanding and managing fecal urgency in inflammatory bowel diseases – Clinical Gastroenterology and Hepatology

 

Review | Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension

4 May, 2023 | 13:36h | UTC

Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension – Liver International

 

Review | Lynch syndrome genetics and clinical implications

4 May, 2023 | 13:24h | UTC

Lynch syndrome genetics and clinical implications – Gastroenterology

 

SR | Fecal microbiota transplantation effective in recurrent C. difficile treatment

3 May, 2023 | 15:29h | UTC

Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile) – Cochrane Library

Summary: Stool transplantation for treatment of repeated Clostridioides difficile infection – Cochrane Library

Commentaries:

Cochrane study finds stool transplants more effective than antibiotics for treating recurring, life-threatening gut infections – Cochrane Library

Expert reaction to two Cochrane reviews looking at stool transplants for recurrent Clostridium difficile infection, and for inflammatory bowel disease – Science Media Centre

Fecal microbiota transplant: Effective solution for recurrent C. difficile infections – News Medical

Related:

RCT | Fecal microbiota transplantation better than standard of care for first or second Clostridioides difficile infection.

Long-term safety of fecal microbiota transplantation for recurrent Clostridioides difficile infection

 

Commentary on Twitter

 

Consensus definition of sludge and microlithiasis as a possible cause of pancreatitis

3 May, 2023 | 15:22h | UTC

Consensus definition of sludge and microlithiasis as a possible cause of pancreatitis – Gut

 

RCT | High vs. low target mean arterial pressure in patients with cirrhosis and septic shock

3 May, 2023 | 15:01h | UTC

A randomized-controlled trial (TARGET-C) of high vs. low target mean arterial pressure in patients with cirrhosis and septic shock – Journal of Hepatology

 

SR | Fecal transplantation for treatment of inflammatory bowel disease

2 May, 2023 | 13:39h | UTC

Fecal transplantation for treatment of inflammatory bowel disease – Cochrane Library

Commentary: Expert reaction to two Cochrane reviews looking at stool transplants for recurrent Clostridium difficile infection, and for inflammatory bowel disease – Science Media Centre

 

Review | Helicobacter pylori infection

2 May, 2023 | 13:37h | UTC

Helicobacter pylori infection – Nature Reviews Disease Primers (if the link is paywalled, try this one)

 

Commentary on Twitter

 

RCT | Molecular point-of-care testing for gastroenteritis reduced isolation time but increased antibiotic use

28 Apr, 2023 | 13:15h | UTC

Clinical impact of syndromic molecular point-of-care testing for gastrointestinal pathogens in adults hospitalised with suspected gastroenteritis (GastroPOC): a pragmatic, open-label, randomised controlled trial – The Lancet Infectious Diseases

Commentary: Molecular testing in suspected infectious diarrhoea—the value of negative results – The Lancet Infectious Diseases

 

RCT | Anti-TNF in combination with low dose methotrexate vs anti-TNF monotherapy in pediatric Crohn’s disease

26 Apr, 2023 | 13:55h | UTC

Comparative Effectiveness of Anti-TNF in Combination with Low Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn’s Disease: a Pragmatic Randomized Trial – Gastroenterology (link to abstract – $ for full-text)

News Release: Researchers Announce Findings from Landmark Clinical Trial for Pediatric Crohn’s Disease – University of North Carolina Health Care System

 

AGA Practical Guidance | Diagnosis and management of extraesophageal gastroesophageal reflux disease

25 Apr, 2023 | 14:50h | UTC

AGA Clinical Practice Update on the Diagnosis and Management of Extraesophageal Gastroesophageal Reflux Disease: Expert Review – Clinical Gastroenterology and Hepatology

Commentary: Guidance offered on management of extraesophageal GERD – ACP Gastroenterology

 

Commentary on Twitter (thread – click for more)

 

Review | New treatment paradigms in primary biliary cholangitis

26 Apr, 2023 | 13:49h | UTC

New Treatment Paradigms in Primary Biliary Cholangitis – Clinical Gastroenterology and Hepatology

 

Stay Updated in Your Specialty

No spam, just news.